159 related articles for article (PubMed ID: 35875063)
21. Tandem duplications of MLL and FLT3 are correlated with poor prognoses in pediatric acute myeloid leukemia: a study of the Japanese childhood AML Cooperative Study Group.
Shimada A; Taki T; Tabuchi K; Taketani T; Hanada R; Tawa A; Tsuchida M; Horibe K; Tsukimoto I; Hayashi Y
Pediatr Blood Cancer; 2008 Feb; 50(2):264-9. PubMed ID: 17763464
[TBL] [Abstract][Full Text] [Related]
22. The prognosis predictive value of FMS-like tyrosine kinase 3-internal tandem duplications mutant allelic ratio (FLT3-ITD MR) in patients with acute myeloid leukemia detected by GeneScan.
Lyu M; Liao H; Shuai X; Jin Y; Su J; Zheng Q
Gene; 2020 Feb; 726():144195. PubMed ID: 31669649
[TBL] [Abstract][Full Text] [Related]
23. Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution.
DeZern AE; Sung A; Kim S; Smith BD; Karp JE; Gore SD; Jones RJ; Fuchs E; Luznik L; McDevitt M; Levis M
Biol Blood Marrow Transplant; 2011 Sep; 17(9):1404-9. PubMed ID: 21324374
[TBL] [Abstract][Full Text] [Related]
24. FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance.
Zwaan CM; Meshinchi S; Radich JP; Veerman AJ; Huismans DR; Munske L; Podleschny M; Hählen K; Pieters R; Zimmermann M; Reinhardt D; Harbott J; Creutzig U; Kaspers GJ; Griesinger F
Blood; 2003 Oct; 102(7):2387-94. PubMed ID: 12816873
[TBL] [Abstract][Full Text] [Related]
25. Internal tandem duplications of the FLT3 and MLL genes are mainly observed in atypical cases of therapy-related acute myeloid leukemia with a normal karyotype and are unrelated to type of previous therapy.
Christiansen DH; Pedersen-Bjergaard J
Leukemia; 2001 Dec; 15(12):1848-51. PubMed ID: 11753604
[TBL] [Abstract][Full Text] [Related]
26. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.
Sasaki K; Kantarjian HM; Kadia T; Patel K; Loghavi S; Garcia-Manero G; Jabbour EJ; DiNardo C; Pemmaraju N; Daver N; Dalle IA; Short N; Yilmaz M; Bose P; Naqvi K; Pierce S; Yalniz F; Cortes JE; Ravandi F
Cancer; 2019 Nov; 125(21):3755-3766. PubMed ID: 31310323
[TBL] [Abstract][Full Text] [Related]
27. High fms-like tyrosine kinase-3 (FLT3) receptor surface expression predicts poor outcome in
Sharawat SK; Raina V; Kumar L; Sharma A; Bakhshi R; Vishnubhatla S; Gupta R; Bakhshi S
Indian J Med Res; 2016 May; 143(Supplement):S11-S16. PubMed ID: 27748272
[TBL] [Abstract][Full Text] [Related]
28. [Diagnosis and treatment efficacy analysis of 29 children with mixed phenotype acute leukemia].
Chen X; Liu F; Guo Y; Zhao BB; Zhang RR; Yang WY; Chen XJ; Zhu XF
Zhonghua Er Ke Za Zhi; 2020 Oct; 58(10):807-812. PubMed ID: 32987459
[No Abstract] [Full Text] [Related]
29. Real world use of FLT3 inhibitors for treatment of FLT3+ acute myeloid leukemia (AML): A single center, propensity-score matched, retrospective cohort study.
Bazzell BG; Marini BL; Benitez LL; Bixby D; Burke P; Pettit K; Perissinotti AJ
J Oncol Pharm Pract; 2022 Sep; 28(6):1315-1325. PubMed ID: 34074182
[TBL] [Abstract][Full Text] [Related]
30. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis.
Brunet S; Labopin M; Esteve J; Cornelissen J; Socié G; Iori AP; Verdonck LF; Volin L; Gratwohl A; Sierra J; Mohty M; Rocha V
J Clin Oncol; 2012 Mar; 30(7):735-41. PubMed ID: 22291086
[TBL] [Abstract][Full Text] [Related]
31. Prognostic factors in normal karyotype acute myeloid leukemia in the absence of the FLT3-ITD mutation.
Jiang A; Jiang H; Brandwein J; Kamel-Reid S; Chang H
Leuk Res; 2011 Apr; 35(4):492-8. PubMed ID: 20684989
[TBL] [Abstract][Full Text] [Related]
32. Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation.
Antar A; Kharfan-Dabaja MA; Mahfouz R; Bazarbachi A
Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):298-302. PubMed ID: 25550214
[TBL] [Abstract][Full Text] [Related]
33. [Clinical Characteristics and Prognosis of Acute Myeloid Leukemia with FLT3-ITD Mutation].
Liu Y; Ke XY; Wang J; Wang JJ; Jing HM; Dong F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Apr; 26(2):354-358. PubMed ID: 29665898
[TBL] [Abstract][Full Text] [Related]
34. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
[TBL] [Abstract][Full Text] [Related]
35. Favorable long-term survival using consolidation chemotherapy without allogeneic hematopoietic cell transplantation for acute myeloid leukemia with wild-type
Baek DW; Lee JM; Kim JH; Cho HJ; Ham JY; Suh JS; Sohn SK; Moon JH
Blood Res; 2019 Sep; 54(3):189-197. PubMed ID: 31730679
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Significance of Fms-Like Tyrosine Kinase 3 Internal Tandem Duplication Mutation in Non-Transplant Adult Patients with Acute Myeloblastic Leukemia: A Systematic Review and Meta-Analysis.
Rinaldi I; Louisa M; Wiguna FI; Budiani E; Mahardhika JC; Hukmi K
Asian Pac J Cancer Prev; 2020 Oct; 21(10):2827-2836. PubMed ID: 33112537
[TBL] [Abstract][Full Text] [Related]
37. [FMS-like tyrosine kinase 3 gene mutations in acute myeloid leukemia].
Han YL; Zhang SJ; Qiao C; Dai D; Sun XM; Xu YL; Qian SX; Xu W; Wang JS; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Oct; 17(5):1135-9. PubMed ID: 19840437
[TBL] [Abstract][Full Text] [Related]
38. Comparison of anthracyclines used for induction chemotherapy in patients with FLT3-ITD-mutated acute myeloid leukemia.
Choi EJ; Lee JH; Lee JH; Park HS; Ko SH; Hur EH; Moon J; Goo BK; Kim Y; Seol M; Lee YS; Kang YA; Jeon M; Woo JM; Lee KH
Leuk Res; 2018 May; 68():51-56. PubMed ID: 29544132
[TBL] [Abstract][Full Text] [Related]
39. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
40. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.
Whitman SP; Archer KJ; Feng L; Baldus C; Becknell B; Carlson BD; Carroll AJ; Mrózek K; Vardiman JW; George SL; Kolitz JE; Larson RA; Bloomfield CD; Caligiuri MA
Cancer Res; 2001 Oct; 61(19):7233-9. PubMed ID: 11585760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
